Wednesday, 26 January 2022

Generic Lidex Ointment by Lupin receives FDA approval

03 August 2017 | News

Lidex Ointment had US sales of USD 40.3 million

Source: Pixabay

Source: Pixabay

Pharma company Lupin Limited has announced that United States Food and Drug Administration (USFDA) has finally approved its Fluocinonide Topical Ointment USP, 0.05% to market a generic version of County Line Pharmaceuticals, LLC’s Lidex Ointment, 0.05%.

Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Lupin’s Fluocinonide Topical Ointment USP, 0.05% is AB rated generic equivalent of LLC’s Lidex Ointment, 0.05%.

Lidex Ointment had US sales of USD 40.3 million (IMS MAT March 2017).

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account